Literature DB >> 21175443

Evaluation of a QT nomogram for risk assessment after antidepressant overdose.

W Stephen Waring1, Ann Graham, Julie Gray, Allen D Wilson, Catherine Howell, D Nicholas Bateman.   

Abstract

AIMS: A QT-heart rate nomogram has recently been proposed as a means of identifying patients at risk of torsades de pointes after antidepressant overdose, based on published cases of drug-induced torsades de pointes. The present study sought to examine the performance of the nomogram in patients who ingest an antidepressant overdose but do not develop arrhythmia.
METHODS: A retrospective case control study of patients presenting to hospital after overdose of citalopram, mirtazapine and venlafaxine was carried out. The primary outcome variable was QT higher than the nomogram, and was compared with occurrence of QT(c) (QT corrected by Bazett's formula) greater than ≥440 ms and QT(c) ≥500 ms, with comparison between drugs. Data are expressed as proportions in each group with 95% confidence intervals.
RESULTS: There were 858 electrocardiograms from 541 patients. QT was higher than the nomogram in 2.4% (1.4, 4.1%), whereas QT(c) was ≥440 ms in 23.1% (95% CI 19.8, 26.8%), and QT(c) was ≥500 ms in 1.1% (0.5, 2.5%). Citalopram overdose was more likely to be associated with QT higher than the nomogram compared with the other agents (difference 7.0%, 95% CI 2.9, 11.9%, P = 0.001) and more likely to be associated with QT(c) ≥440 ms (difference = 11.0%, 95% CI 2.6, 19.0%, P = 0.013).
CONCLUSIONS: The QT nomogram was associated with a lower false positive rate than widely accepted QT(c) criteria, and allowed detection of different effects of individual drugs. The nomogram offers potential advantages over QT(c) criteria and merits further investigation in a clinical setting.
© 2010 The Authors. British Journal of Clinical Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175443      PMCID: PMC3014071          DOI: 10.1111/j.1365-2125.2010.03728.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval.

Authors:  Julia H Indik; Ellen C Pearson; Karen Fried; Raymond L Woosley
Journal:  Heart Rhythm       Date:  2006-06-15       Impact factor: 6.343

Review 2.  Drug-induced long QT and torsade de pointes: recent advances.

Authors:  Prince J Kannankeril; Dan M Roden
Journal:  Curr Opin Cardiol       Date:  2007-01       Impact factor: 2.161

3.  QT interval prolongation associated with venlafaxine administration.

Authors:  Konstantinos Letsas; Panagiotis Korantzopoulos; Loucas Pappas; Dimitrios Evangelou; Michalis Efremidis; Fotis Kardaras
Journal:  Int J Cardiol       Date:  2006-04-28       Impact factor: 4.164

4.  Clinical assessment of drug-induced QT prolongation in association with heart rate changes.

Authors:  Fabrice Extramiana; Pierre Maison-Blanche; Marie-José Cabanis; Catherine Ortemann-Renon; Philippe Beaufils; Antoine Leenhardt
Journal:  Clin Pharmacol Ther       Date:  2005-04       Impact factor: 6.875

5.  Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.

Authors:  G A Christie; C Lucas; D N Bateman; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

6.  Subject-specific heart rate dependency of electrocardiographic QT, PQ, and QRS intervals.

Authors:  Marek Malik; Katerina Hnatkova; Martina Sisakova; Georg Schmidt
Journal:  J Electrocardiol       Date:  2008-09-24       Impact factor: 1.438

7.  Quetiapine poisoning: a case series.

Authors:  Corrine R Balit; Geoffrey K Isbister; L Peter Hackett; Ian M Whyte
Journal:  Ann Emerg Med       Date:  2003-12       Impact factor: 5.721

Review 8.  Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.

Authors:  Michela Sala; Fabio Coppa; Corrado Cappucciati; Paolo Brambilla; Giorgio d'Allio; Edgardo Caverzasi; Francesco Barale; Gaetano M De Ferrari
Journal:  Curr Opin Investig Drugs       Date:  2006-03

9.  Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition.

Authors:  Anthony A Fossa; Todd Wisialowski; Anthony Magnano; Eric Wolfgang; Roxanne Winslow; William Gorczyca; Kimberly Crimin; David L Raunig
Journal:  J Pharmacol Exp Ther       Date:  2004-08-11       Impact factor: 4.030

10.  The limited utility of electrocardiography variables used to predict arrhythmia in psychotropic drug overdose.

Authors:  Nicholas A Buckley; Stephan Chevalier; I Anne Leditschke; Dianne L O'Connell; James Leitch; Susan M Pond
Journal:  Crit Care       Date:  2003-08-18       Impact factor: 9.097

View more
  19 in total

1.  Editors' pick 2010.

Authors:  Yoon K Loke; Albert Ferro; Lionel D Lewis; Adam F Cohen; Andrew Somogyi; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

2.  Lack of relationship between plasma levels of escitalopram and QTc-interval length.

Authors:  Mar Carceller-Sindreu; Javier de Diego-Adeliño; Maria J Portella; Xavier Garcia-Moll; Maria Figueras; Aina Fernandez-Vidal; Josep M Queraltó; Dolors Puigdemont; Enric Álvarez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-01-23       Impact factor: 5.270

Review 3.  Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.

Authors:  Geoffrey K Isbister; Colin B Page
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

Review 4.  Towards a better understanding of QT interval variability.

Authors:  Larisa G Tereshchenko; Ronald D Berger
Journal:  Ther Adv Drug Saf       Date:  2011-12

5.  Solifenacin linked QT interval prolongation and torsades de pointes.

Authors:  Jonathan J H Bray; Jules C Hancox
Journal:  Ther Adv Drug Saf       Date:  2017-04-10

6.  Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Authors:  Christopher Kogut; Ericka Breden Crouse; W Victor R Vieweg; Mehrul Hasnain; Adrian Baranchuk; Geneviève C Digby; Jayanthi N Koneru; Antony Fernandez; Anand Deshmukh; Jules C Hancox; Ananda K Pandurangi
Journal:  Ther Adv Drug Saf       Date:  2013-10

Review 7.  Citalopram and cardiac toxicity.

Authors:  M J Cooke; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

8.  Citalopram and escitalopram: adverse cardiac outcomes in medically ill inpatients.

Authors:  Dominique Elie; Saeid Noohi; André Do; Artin Mahdanian; Ching Yu; Marilyn Segal; Karl J Looper; Soham Rej
Journal:  Ther Adv Drug Saf       Date:  2016-07-19

Review 9.  Drug-induced QT interval prolongation: mechanisms and clinical management.

Authors:  Senthil Nachimuthu; Manish D Assar; Jeffrey M Schussler
Journal:  Ther Adv Drug Saf       Date:  2012-10

Review 10.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.